Company / Operating Cash Flow
Tandem Diabetes Care Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$9.7M
FY2025
5-year range
-$31.8M / $41.9M
FY2021-FY2025
Trend
-140.1%
vs FY2024
Sector context
#142 of 164
Health Care
What the data says
Tandem Diabetes Care's operating cash flow of -$10M is lower than 87% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$66M in FY2019 to $42M in FY2021.
Based on SEC 10-K filings.
-$10M in FY2025.
Improved from -$32M to -$10M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 164This company -$9.7M Sector average $1.0B
▼
-100.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 140.1% year-over-year.
- Ranks #142 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
- Lowest operating cash flow in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$9.7M | -140.1% |
| FY2024 | $24.2M | +176.2% |
| FY2023 | -$31.8M | -228.9% |
| FY2022 | $24.7M | -41.1% |
| FY2021 | $41.9M | +603.7% |
| FY2020 | -$8.3M | +87.4% |
| FY2019 | -$66.1M | -8.1% |
| FY2018 | -$61.2M | -4.1% |
| FY2017 | -$58.8M | +3.9% |
| FY2016 | -$61.2M | -4.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026